We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AbbVie (ABBV) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
AbbVie (ABBV - Free Report) closed the most recent trading day at $142.94, moving +0.01% from the previous trading session. The stock outpaced the S&P 500's daily loss of 2.37%. At the same time, the Dow lost 1.35%, and the tech-heavy Nasdaq lost 0.21%.
Prior to today's trading, shares of the drugmaker had gained 0.29% over the past month. This has outpaced the Medical sector's loss of 3.73% and the S&P 500's loss of 6.51% in that time.
Wall Street will be looking for positivity from AbbVie as it approaches its next earnings report date. This is expected to be October 28, 2022. In that report, analysts expect AbbVie to post earnings of $3.57 per share. This would mark year-over-year growth of 7.21%. Our most recent consensus estimate is calling for quarterly revenue of $14.92 billion, up 4.01% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $13.92 per share and revenue of $59.02 billion, which would represent changes of +9.61% and +5.02%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for AbbVie. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 1.37% lower. AbbVie is currently sporting a Zacks Rank of #4 (Sell).
Investors should also note AbbVie's current valuation metrics, including its Forward P/E ratio of 10.27. This represents a discount compared to its industry's average Forward P/E of 12.58.
Meanwhile, ABBV's PEG ratio is currently 4.05. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 1.75 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 135, which puts it in the bottom 47% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow ABBV in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
AbbVie (ABBV) Gains As Market Dips: What You Should Know
AbbVie (ABBV - Free Report) closed the most recent trading day at $142.94, moving +0.01% from the previous trading session. The stock outpaced the S&P 500's daily loss of 2.37%. At the same time, the Dow lost 1.35%, and the tech-heavy Nasdaq lost 0.21%.
Prior to today's trading, shares of the drugmaker had gained 0.29% over the past month. This has outpaced the Medical sector's loss of 3.73% and the S&P 500's loss of 6.51% in that time.
Wall Street will be looking for positivity from AbbVie as it approaches its next earnings report date. This is expected to be October 28, 2022. In that report, analysts expect AbbVie to post earnings of $3.57 per share. This would mark year-over-year growth of 7.21%. Our most recent consensus estimate is calling for quarterly revenue of $14.92 billion, up 4.01% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $13.92 per share and revenue of $59.02 billion, which would represent changes of +9.61% and +5.02%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for AbbVie. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 1.37% lower. AbbVie is currently sporting a Zacks Rank of #4 (Sell).
Investors should also note AbbVie's current valuation metrics, including its Forward P/E ratio of 10.27. This represents a discount compared to its industry's average Forward P/E of 12.58.
Meanwhile, ABBV's PEG ratio is currently 4.05. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 1.75 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 135, which puts it in the bottom 47% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow ABBV in the coming trading sessions, be sure to utilize Zacks.com.